ATE304351T1 - Arzneizubereitungen enthaltend kannabinoide - Google Patents

Arzneizubereitungen enthaltend kannabinoide

Info

Publication number
ATE304351T1
ATE304351T1 AT04075590T AT04075590T ATE304351T1 AT E304351 T1 ATE304351 T1 AT E304351T1 AT 04075590 T AT04075590 T AT 04075590T AT 04075590 T AT04075590 T AT 04075590T AT E304351 T1 ATE304351 T1 AT E304351T1
Authority
AT
Austria
Prior art keywords
preparations containing
medicinal preparations
containing cannabinoids
cannabinoids
medicinal
Prior art date
Application number
AT04075590T
Other languages
English (en)
Inventor
Peter James Watts
Stanley Stewart Davis
Original Assignee
Archimedes Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd
Application granted granted Critical
Publication of ATE304351T1 publication Critical patent/ATE304351T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04075590T 1997-12-19 1998-12-10 Arzneizubereitungen enthaltend kannabinoide ATE304351T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726916.1A GB9726916D0 (en) 1997-12-19 1997-12-19 Nasal formulation

Publications (1)

Publication Number Publication Date
ATE304351T1 true ATE304351T1 (de) 2005-09-15

Family

ID=10823941

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04075590T ATE304351T1 (de) 1997-12-19 1998-12-10 Arzneizubereitungen enthaltend kannabinoide

Country Status (13)

Country Link
US (1) US6383513B1 (de)
EP (2) EP1437136B1 (de)
JP (1) JP2001526221A (de)
AR (1) AR017898A1 (de)
AT (1) ATE304351T1 (de)
AU (1) AU756669B2 (de)
CA (1) CA2313316A1 (de)
DE (1) DE69831620D1 (de)
GB (1) GB9726916D0 (de)
NO (1) NO20003161D0 (de)
NZ (1) NZ504679A (de)
WO (1) WO1999032107A1 (de)
ZA (1) ZA9811528B (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US7648696B2 (en) 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
ATE353629T1 (de) * 2000-03-09 2007-03-15 Gw Pharma Ltd Cannabis enthaltende pharmazeutische zusammensetzungen
GB2361869B (en) * 2000-03-09 2004-09-22 Pharmasol Ltd Sublingual delivery of cannabis
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
CA2438097C (en) * 2001-02-14 2006-04-25 Gw Pharma Limited Cannabinoids pharmaceutical formulations
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
ES2332584T3 (es) * 2001-03-27 2010-02-09 Phares Pharmaceutical Research N.V. Metodo y composicion para solubilizar un compuesto biologicamente activo con baja solubilidad en agua.
WO2003006010A1 (en) * 2001-07-10 2003-01-23 Norton Healthcare Limited Aerosol formulations of δ8 tetrahydrocannabinol
EP1321159A1 (de) * 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Betätigungsvorrichtung für Druckdosierinhalator mit lasergebohrten Löchern
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
EP1482917B1 (de) * 2002-02-01 2019-05-08 GW Pharma Limited Zusammensetzungen mit cannabidiolsäure zur behandlung von übelkeit, erbrechen, emesis, reisekrankheit oder ähnlichen zuständen
EP1474412B1 (de) * 2002-02-01 2008-05-28 Resolution Chemicals Limited Gewinnung von delta-9 tetrahydrocannabinol
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
FI111733B (fi) 2002-02-20 2003-09-15 Pedipharm Oy Uudet metyloidut syklodekstriinikompleksit
FI113340B (fi) * 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
AU2003240759B2 (en) * 2002-04-03 2008-02-14 Solvay Pharmaceuticals B.V. Stabilized natural cannabinoid formulation
AR039194A1 (es) 2002-04-03 2005-02-09 Solvay Pharm Bv Formulacion de cannabinoides naturales estabilizados
CA2487882A1 (en) * 2002-05-31 2003-12-11 University Of Mississippi Transmucosal delivery of cannabinoids
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US20040228921A1 (en) * 2003-02-14 2004-11-18 Chowdhury Dipak K. Compositions and methods for delivery of therapeutic agents
AU2004230871A1 (en) * 2003-04-10 2004-10-28 Mallinckrodt Inc. Olivetol-cyclodextrin complexes and regio-selective process for preparing delta 9-tetrahydrocannabinol
CA2523870A1 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
JP2006525354A (ja) * 2003-05-01 2006-11-09 アルキメデス・ディヴェロップメント・リミテッド Ｌｈ−ｒｈアナログロイプロイドの経鼻投与
WO2005055945A2 (en) * 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
EP1768647B1 (de) 2004-06-17 2012-08-08 Virun, Inc. Zusammensetzungen mit mukoadhäsivem protein und wirkstoff zur mukosalen abgabe dieses mittels
US20060078955A1 (en) * 2004-10-13 2006-04-13 Lin-Zhi International Method for retrieving delta9-THC from oral fluid
TWI436991B (zh) * 2004-11-22 2014-05-11 歐 賽提克股份有限公司 用於純化反-（-）-△９-四氫大麻酚與反-（＋）-△９-四氫大麻酚之方法
CN101132781A (zh) 2004-12-09 2008-02-27 茵西斯医疗公司 在室温下稳定的屈大麻酚剂型
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2007032962A2 (en) * 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
JP2009514890A (ja) * 2005-11-07 2009-04-09 マーティ・ファーマシューティカルズ・インク テトラヒドロカンナビノールの改良された送達
CN101415395B (zh) * 2006-03-29 2012-02-08 富士胶片株式会社 酪蛋白纳米粒子
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
PL2061427T3 (pl) * 2006-09-15 2011-12-30 Echo Pharmaceuticals Bv Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
EP2184983A1 (de) * 2007-08-06 2010-05-19 Insys Therapeutics Inc. Orale cannabinoid-flüssigformulierungen und behandlungsverfahren
US8735374B2 (en) 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
US10653787B2 (en) 2014-03-18 2020-05-19 Izun Pharmaceuticals Corp Water-based cannabinoid and opioid compositions
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
CA3111682A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US20160143972A1 (en) * 2014-11-21 2016-05-26 Cannamark Inc. Method and apparatus for preparing a solid form of cannabinoid
MX386351B (es) * 2015-01-31 2025-03-18 Constance Therapeutics Inc Métodos para la preparación de extractos y composiciones de aceite de cannabis.
AU2016231788A1 (en) * 2015-03-19 2017-10-12 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
WO2016186735A1 (en) 2015-05-18 2016-11-24 5071, Inc. Homogenous cannabis compositions and methods of making the same
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
BR102015024165A2 (pt) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
CA3006182A1 (en) * 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
EP3405175A4 (de) * 2016-01-20 2019-09-25 Flurry Powders, LLC Verkapselung von lipophilen inhaltsstoffen in dispergierbaren sprühgetrockneten inhalierbaren pulvern
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
US10617636B2 (en) 2016-04-15 2020-04-14 Sre Wellness, Inc. Cannabis infused sweeteners and elixirs
US20180206518A1 (en) * 2016-04-15 2018-07-26 Ronald Silver Method of making cannabis oil hydrophilic using emulsifiers and related cannabinoid compositions
US20220087972A9 (en) 2016-04-15 2022-03-24 Sre Wellness, Inc. Cannabinoid Compositions
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
BR112018075073A2 (pt) * 2016-06-02 2019-04-30 Acerus Pharmaceutical Corporation composições nasais de canabidiol
US20180085308A1 (en) * 2016-09-27 2018-03-29 CannTab Therapeutics Limited Sustained release cannabinoid formulations
CA3053158A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
US12016838B2 (en) * 2017-03-09 2024-06-25 Day Three Labs Manufacturing Inc. Stabilized protein-bound cannabinoid compositions
KR102621425B1 (ko) * 2017-03-16 2024-01-05 이준 파마슈티컬스 코퍼레이션 칸나비노이드 제형 및 투여량
EP3644986A4 (de) * 2017-05-01 2021-01-06 MJ Wooly Corporation Methodologie und formulierung zur erzeugung von pulver einer verkapselten, cannabisbasierten komponente, die in einer polymermatrix eingebettet ist
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
EP3638053A1 (de) 2017-06-16 2020-04-22 Sorse Technology Corporation Herstellung stabiler flüssiger emulsionsformen eines pflanzenextraktes
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
WO2019014631A1 (en) * 2017-07-14 2019-01-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
EP3717014A1 (de) 2017-11-29 2020-10-07 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cannabinoide zusammensetzungen und verfahren
CA3076963C (en) * 2017-11-30 2022-03-29 Canopy Growth Corporation Liquid dosage forms comprising cannabis, methods of making and use
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US20200330378A1 (en) * 2018-01-03 2020-10-22 Icdpharma Ltd. Taste-enhanced cannabinoid submicron emulsion syrup compositions
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2019211771A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Water soluble and water dispersible formulations of cannabinoids
EP3823595A1 (de) 2018-07-18 2021-05-26 Glatt Gmbh Cannabinoidformulierungen mit verlängerter freisetzung
US10383819B1 (en) 2018-07-23 2019-08-20 Callitas Therapeutics, Inc. Method to effect biphasic bioavailability of oral euphoric psychogenic cannabinoids
US20220008348A1 (en) * 2018-11-08 2022-01-13 Michael Golfetto Compound delivery systems and methods of production
US20200170962A1 (en) 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
CA3138185A1 (en) * 2019-05-13 2020-11-19 Buzzkill Labs, Inc. Processing cartridge for portable drug testing system
DE102019211195A1 (de) * 2019-07-26 2021-01-28 Add Advanced Drug Delivery Technologies Ltd. Verfahren und Vorrichtung zur Herstellung eines im Wesentlichen im wässrigen Milieu lösbaren Cannabinoid-Granulats
WO2021046189A1 (en) 2019-09-06 2021-03-11 Quicksilver Scientific, Inc. Microemulsion delivery systems for water-based beverages
KR20240134147A (ko) * 2019-10-21 2024-09-06 이솔레이트 엘티디 초미세 화합물 및 이의 제조
CN112891310A (zh) * 2019-12-03 2021-06-04 晨光生物科技集团股份有限公司 一种大麻二酚粉末的制备方法、制备得到的大麻二酚粉末及其用途
WO2021111446A1 (en) * 2019-12-05 2021-06-10 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Biodegradable polymeric compositions, methods of preparation and uses thereof
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
TW202210072A (zh) * 2020-05-26 2022-03-16 美商羅德科技公司 用於鼻內或吸入遞送之大麻素組合物及劑型
EP3919046A1 (de) 2020-06-02 2021-12-08 Athenion AG Verfahren zur solubilisierung von natürlichen, endogenen und synthetischen cannabinoiden
WO2022011393A1 (en) 2020-07-08 2022-01-13 Shaman Naturals, Llc Compositions for preventing and treating diabetes
AU2021308671A1 (en) 2020-07-17 2023-03-02 Canna-Chemistries Llc Solid Δ9-tetrahydrocannabinol ( Δ9-THC) compositions
US20260069611A1 (en) 2024-09-06 2026-03-12 A2W Pharma Limited Stable cannabidiol oral formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
DE3688617T2 (de) * 1986-11-03 1993-11-18 Allen W Jacobs Verfahren zur Beimischung einer festen teilchenförmigen Komponente in Aerosolpräparate zur Inhalation des Nikotins.
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US6096740A (en) * 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
IL115245A (en) * 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
JP2001507701A (ja) * 1996-12-31 2001-06-12 インヘイル・セラピューティック・システムズ・インコーポレーテッド 親水性賦形剤を有する疎水性薬剤の溶液を噴霧乾燥するための方法及びその方法によって作製された組成物
US5804592A (en) * 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
US5989535A (en) * 1997-08-15 1999-11-23 Soma Technologies Polymeric bioadhesive emulsions and suspensions and methods of treatment

Also Published As

Publication number Publication date
AU1497299A (en) 1999-07-12
NO20003161L (no) 2000-06-16
CA2313316A1 (en) 1999-07-01
AR017898A1 (es) 2001-10-24
EP1437136B1 (de) 2005-09-14
JP2001526221A (ja) 2001-12-18
US6383513B1 (en) 2002-05-07
ZA9811528B (en) 2000-10-12
DE69831620D1 (de) 2005-10-20
EP1039898A1 (de) 2000-10-04
NO20003161D0 (no) 2000-06-16
AU756669B2 (en) 2003-01-23
NZ504679A (en) 2002-06-28
GB9726916D0 (en) 1998-02-18
WO1999032107A1 (en) 1999-07-01
EP1437136A1 (de) 2004-07-14

Similar Documents

Publication Publication Date Title
ATE304351T1 (de) Arzneizubereitungen enthaltend kannabinoide
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
DE69800639D1 (de) Tetrahydrolipstatin enthaltende präparate
IS5425A (is) Læknislyf
DE69530325D1 (de) Aerosol-arzneiformulierungen
FI973243A0 (fi) Uusi farmaseuttinen yhdistelmä
ID24654A (id) Formulasi farmasi omeprazola
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
DE69632753D1 (de) Darifenacin enthaltende pharmazeutische Zubereitungen
DK0981375T3 (da) Farmaceutiske præparater indeholdende plasmaprotein
NO995712D0 (no) Oftalmiske preparater
ATE266383T1 (de) Dermatologische zubereitungen
ATE288419T1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
ATE332132T1 (de) Verbesserte arzneizubereitungen enthaltend ritonavir
DE69705628D1 (de) Chlorfluorkohlenwasserstoff freie aerosol-arzneizubereitungen enthaltend mometasonfuroat
EP0907644A4 (de) Pharmazeutische zubereitung
ATE298576T1 (de) Arzneizubereitungen
IS5062A (is) Lyfjablöndur sem innihalda afleiður N-súlfonýlindólíns
DK0925273T3 (da) Farmaceutiske præparater indeholdende 4-oxo-butansyrer
NO994619L (no) Farmasöytiske blandinger
ITMI941169A0 (it) Formulazioni farmaceutiche
EE03511B1 (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
DK1041966T3 (da) Farmaceutiske præparater omfattende zafirlukast
ATE237309T1 (de) Arzneizubereitungen
EP1142589A4 (de) Medizinische zusammensetzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties